Search Results

Press Releases

Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

January 16, 2025

·

7 min read

Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients

Mainstay Medical Holdings plc announced the publication of a pooled analysis of three different clinical studies that evaluated the safety and efficacy of ReActiv8 therapy after two years in patients of various ages.

March 12, 2024

·

4 min read

FDA

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation System TM.

February 12, 2024

·

3 min read

Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up

Mainstay Medical Holdings plc announced the publication of the 5-year follow up from the ReActiv8-B randomized, sham-controlled, double-blinded trial.

March 19, 2024

·

4 min read

Press Releases

Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM

July 9, 2024

·

3 min read

Mainstay Medical Announces Completion of Enrollment of RESTORE Clinical Trial of ReActiv8® in the United States

Mainstay Medical Holdings plc today announced the completion of enrollment in its RESTORE randomized clinical study of ReActiv8 for the treatment of intractable chronic low back pain.

August 29, 2023

·

6 min read

Mainstay Medical Announces Publication of Three-Year Clinical Trial Data from Post-Market Clinical Follow-up Registry of ReActiv8® in the United Kingdom

Mainstay Medical Holdings plc today announced the publication of three-year clinical data from the Post-Market Clinical Follow-up (PMCF) study of 33 ReActiv8 patients from five medical centres across the United Kingdom.

July 20, 2023

·

4 min read

Policy

FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS)

QIAGEN announced that the U.S. Federal Bureau of Investigation has approved its ForenSeq® MainstAY workflow.

June 20, 2023

·

7 min read

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™

Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial.

September 28, 2022

·

5 min read

Business

Mainstay Medical Announces Appointment of Jeffrey Dunn and Eric Major to its Board of Directors

Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company’s board of directors, Jeffrey Dunn and Eric Major.

December 14, 2021

·

4 min read